Edwards Lifesciences (EW)
(Delayed Data from NYSE)
$92.85 USD
-0.93 (-0.99%)
Updated Jul 11, 2024 04:00 PM ET
After-Market: $92.85 0.00 (0.00%) 6:22 PM ET
3-Hold of 5 3
D Value D Growth F Momentum F VGM
Price, Consensus and EPS Surprise
EW 92.85 -0.93(-0.99%)
Will EW be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for EW based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for EW
HOLX vs. EW: Which Stock Is the Better Value Option?
Universal Health (UHS) Gains 28% in a Year: What Lies Ahead?
EW: What are Zacks experts saying now?
Zacks Private Portfolio Services
HOLX vs. EW: Which Stock Should Value Investors Buy Now?
BD (BDX) Inks Buyout Deal to Expand Smart Connected Care Suite
Why Is Idexx (IDXX) Up 5% Since Last Earnings Report?
Other News for EW
Robbie Marcus Reiterates Buy Rating on Edwards Lifesciences Citing Growth and Clinical Outcomes
The best of breed global stocks for 3Q2024 - BofA
Why Investors Are Eyeing Edwards Lifesciences Corp (EW): The Key Drivers of Market ...
Edwards Lifesciences (EW) Gets a Buy from RBC Capital
Edwards Lifesciences Corp Looks Bullish (Technical Analysis)